Skip to main content

INSIGHTS

Articles, conference updates, market insight and interviews from the Biopharma, Pharma and MedTech communities we convene.

10 pieces shown

  • BiopharmaIndustry article

    Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia

    On 12 November 2026, Eppendorf SE broke ground on a new production facility at Bandar Cassia Technology Park in Penang. The EUR 40 million investment is the company's first manufacturing operation in Southeast Asia and will produce selected products from its Centrifuges & Instruments portfolio for laboratories worldwide, with production starting gradually in 2028.

    Read more: Eppendorf Breaks Ground on a EUR 40 Million Production Site in Penang, Malaysia
  • BiopharmaMarket insight

    Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?

    The first approved CRISPR therapy proved that genome editing can work as a medicine. Asia, home to a large share of the world's patients with inherited blood disorders and a fast-growing research base, is now moving from discovery towards the clinic. This article looks at where the region stands, what is holding it back and what to watch next.

    Read more: Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?
  • PharmaMarket insight

    How the Revised EU GMP Annex 1 Is Reshaping Sterile Fill-Finish in Asia

    The revised EU GMP Annex 1 has moved sterile manufacturing from a checklist of controls to a documented, site-wide contamination control strategy. This article looks at what the revision changed, why it matters well beyond Europe, and how manufacturers and CDMOs across Asia are responding with barrier technology, automation and new fill-finish investment.

    Read more: How the Revised EU GMP Annex 1 Is Reshaping Sterile Fill-Finish in Asia
  • MedTechMarket insight

    Is the JS-SEZ Becoming Southeast Asia’s Next Life Sciences & MedTech Manufacturing Hub?

    The JohorÐSingapore Special Economic Zone (JS-SEZ) has drawn RM88.83 billion (S$28.1 billion) in approved investments in its first 18 months, and a life sciences and MedTech cluster is quietly forming inside it.

    Read more: Is the JS-SEZ Becoming Southeast Asia’s Next Life Sciences & MedTech Manufacturing Hub?
  • BiopharmaMarket insight

    Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?

    Biologics manufacturing productivity depends on more than installed bioreactor volume. This article compares four 2,000 L single-use bioreactors with one 10,000 L stainless-steel reactor and examines how turnaround time, utilisation, titre, downstream capacity and manufacturing strategy can determine annual output.

    Read more: Could Four 2,000 L Single-Use Bioreactors Outperform One 10,000 L Stainless-Steel Reactor?
  • BiopharmaMarket insight

    Stainless Steel vs Single-Use: Why Biomanufacturing Still Needs Both

    Stainless steel and single-use systems serve different roles in modern biomanufacturing, with the right choice depending on production volume, product mix and demand certainty. This article examines how leading APAC facilities are combining scale, flexibility and resilience through steel, single-use and hybrid manufacturing strategies.

    Read more: Stainless Steel vs Single-Use: Why Biomanufacturing Still Needs Both
  • BiopharmaMarket insight

    Why Singapore Is Emerging as Biopharma’s China+1 Hub

    Singapore’s biopharmaceutical sector is navigating short-term production volatility while strengthening its long-term position as a trusted bridge between China and Western markets. This article examines how Singapore’s regulatory credibility, advanced manufacturing ecosystem and geopolitical neutrality support its emerging role as a China+1 hub for global biopharma.

    Read more: Why Singapore Is Emerging as Biopharma’s China+1 Hub
  • BiopharmaMarket insight

    APAC’s Radiopharmaceutical Landscape Is Taking Shape: Where Are the Next Hubs Emerging?

    Asia-Pacific’s radiopharmaceutical sector is expanding as countries invest in isotope production, drug development, specialised manufacturing and theranostics infrastructure. This article examines how Australia, China, Japan, South Korea, India, Singapore and Southeast Asia are developing distinct roles within an increasingly interconnected regional ecosystem.

    Read more: APAC’s Radiopharmaceutical Landscape Is Taking Shape: Where Are the Next Hubs Emerging?
  • MedTechMarket insight

    Indonesia’s MedTech Transformation Is Accelerating

    Indonesia’s MedTech sector is entering a significant period of transformation as investment, technology adoption and international cooperation reshape the market. This article examines how developments across primary healthcare infrastructure, biopharma, digital health and regulation are creating a more connected and resilient MedTech ecosystem.

    Read more: Indonesia’s MedTech Transformation Is Accelerating
  • BiopharmaMarket insight

    Asia’s Biopharma Manufacturing Landscape Is Changing. Where Are the New Hubs Emerging?

    Asia’s biopharmaceutical manufacturing landscape is evolving into a network of specialised ecosystems rather than a single regional hub. This article examines how South Korea, Singapore, China, India, Japan and emerging Southeast Asian markets are developing distinct roles across biologics, advanced therapies and vaccine production.

    Read more: Asia’s Biopharma Manufacturing Landscape Is Changing. Where Are the New Hubs Emerging?